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Abstract
Background: Current theories on the pathophysiology of schizophrenia suggest altered brain plasticity such as decreased
neural proliferation and migration, delayed myelination, and abnormal synaptic modeling, in the brain of subjects with
schizophrenia. Though functional alterations in BDNF, which plays important role in neuroplasticity, are implicated in many
abnormalities found in schizophrenia, the regulatory mechanism(s) involved in the abnormal signaling of BDNF in
schizophrenia is not clear. The present study investigated whether Sprouty2, a regulator of growth factor signaling, is
abnormally expressed in schizophrenia, and is associated with the changes in BDNF mRNA in this disorder. The potential
effect of antipsychotic drugs on Sprouty2 expression was tested in adult rats.
Methods and Findings: Sprouty2 and BDNF gene expression were analyzed in dorsolateral prefrontal cortex samples from
the Stanley Array Collection. Quantitative real-time PCR analysis of RNA in 100 individuals (35 with schizophrenia, 31 with
bipolar disorder, and 34 psychiatrically normal controls) showed significantly decreased expression of Sprouty2 and BDNF in
both schizophrenia and bipolar disorder. Moreover, a significant correlation between these two genes existed in control,
schizophrenia and bipolar subjects. Long-term treatment with antipsychotic drugs, haloperidol and olanzapine, showed
differential effects on both Sprouty2 and BDNF mRNA and protein levels in the frontal cortex of rats.
Conclusion: These findings demonstrating decreased expression of Sprouty2 associated with changes in BDNF, suggest the
possibility that these decreases are secondary to treatment rather than to factors that are significant in the disease process
of either schizophrenia and/or bipolar disorder. Further exploration of Sprouty2-related signal transduction pathways may
be helpful to design novel treatment strategies for these disorders.
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Introduction
Abnormal neurodevelopment (decreased neural proliferation
and migration, delayed myelination, abnormal synaptic modeling)
and subsequent enhanced vulnerability to untreated illness are
implicated in the pathophysiology of schizophrenia [1–3].
Neurotrophic factors exert important actions on the development,
maintenance, and function of the peripheral and central nervous
system [4–7]. For example, deficits in brain derived neurotrophic
factor (BDNF) signaling are implicated in many abnormalities
found in schizophrenia [8–9]. Postmortem studies showed changes
in BDNF as well as its receptor, TrkB expression in different brain
areas of subjects with schizophrenia [10–15]. Although several
studies indicated altered serum BDNF levels in subjects with
schizophrenia [16–18], some other studies failed to find any
difference in serum BDNF levels between drug-naı ¨ve schizophre-
nia and control subjects [19–20]. This discrepancy may be due to
factors such as biological heterogeneity of the subjects, duration of
illness or the antipsychotic medications. More recently, we found a
significant reduction in plasma BDNF levels in subjects with first-
episode psychosis in comparison with normal healthy controls, and
plasma BDNF levels negatively correlated with positive symptom
scores at base line [21]. In addition to the clinical observations,
pre-clinical studies showed that antipsychotic drugs, the primary
choice of treatment for schizophrenia, exert their beneficial effects
through growth factor-mediated signaling pathways [22–23];
however, the regulatory mechanism(s) involved in the abnormal
signaling of BDNF in schizophrenia is not clear.
Recent studies indicate the role for Sprouty (Spry) proteins in
growth factor signaling [24]. Sprouty was first identified in
Drosophila and shares a high degree of evolutionary sequence
homology in the C-terminus, although mammalian Spry differs
from Drosophilia Spry within the N-terminus. Growth factors,
including BDNF, induce Sprouty2 (Spry2, a member of sprouty
family) expression at the transcriptional level and phosphorylate
Spry2 on critical tyrosine residues, suggesting regulation at the
transcriptional and the post-translational level [24–25]. Growth
factor-mediated receptor-tyrosine kinase (RTK) activation leads to
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membrane, where it binds to various signaling molecules such as
Grb-2 [24]. Although Spry proteins inhibit RTK signaling
induced by many growth factors, including BDNF, EGF-mediated
extracellular signal-regulated kinase (ERK)/mitogen-activated
protein kinase (MAPK) signaling is augmented in a cell-type
dependent manner [25]. In vitro studies showed that overexpression
of Spry proteins antagonizes proliferation, migration and differ-
entiation in response to various growth factors [24–25]. In
addition, a recent study showed that Spry2 was involved in the
development of the CNS by inhibiting both neuronal differenti-
ation and survival through a negative-feedback loop that
downregulates BDNF-mediated signaling pathways [26].
Considering neurotrophin involvement in the neuropathogen-
esis of schizophrenia, the possible role of Spry2, a prototypical
member of the sprouty family, was investigated in schizophrenia.
The expression of BDNF and Spry2 was examined by quantitative
real-time PCR (qRT-PCR) in the Stanley Array Collection,
derived from dorsolateral prefrontal cortex (DLPFC) of individuals
with schizophrenia, bipolar disorder, or psychiatrically normal
controls. The study also examined whether the changes in Spry2
mRNA correlated with the changes in BDNF mRNA; changes
which may influence the pathophysiology and pharmacological
treatment of schizophrenic patients.
Results
Sprouty2 expression is decreased in schizophrenia and
bipolar disorder, and correlates with BDNF expression
Reverse-transcription real-time PCR was used for the determi-
nation of mRNA expression levels of Spry2 and BDNF for the
postmortem samples. As shown in Table 1, no significant
correlation was found between the mRNA expression of either
Spry2 or BDNF and the confounding variables, such as age at
death, PMI, brain pH, brain weight, refrigeration interval, gender,
hemisphere, smoking status at time of death, age of onset, duration
of illness, lifetime alcohol use, or lifetime substance abuse.
Furthermore, there was no effect of suicide or cardiac death on
the mRNA expression of Spry2 or BDNF (data not shown).
Next, the possible relationship between the effect of antipsy-
chotic medication and the mRNA expression of Spry2 or BDNF
was examined. The diagnosis status table obtained from Stanley
Foundation on the patients and control subjects indicated that all
schizophrenia patients were treated with antipsychotic drug(s) at
some point during their disease condition. In contrast, a significant
number of patients in bipolar disorder group did not previously
receive (n=12 of 31) antipsychotic medications. No significant
correlation was found between antipsychotic use at time of death
and Spry2 or BDNF mRNA expression in bipolar patients
(Table 2). To understand further the effect of antipsychotic
medication on Spry2 and BDNF, the mRNA levels of spry2 and
BDNF were examined in antipsychotic-naive patients with bipolar
disorder. Spry2 expression was significantly low (p=0.037) in
antipsychotic-naive patients with bipolar disorder (n=12) com-
pared to control subjects. Although mean BDNF mRNA levels
were decreased by 36% in antipsychotic-naive patients with
bipolar disorder, this decrease did not reach statistical significance
(p=0.052). As indicated in Table 2, no significant correlations
were found between levels of lifetime antipsychotic exposure and
expression of either Spry2 or BDNF in schizophrenia group.
A significant reduction in mean Spry2 mRNA levels was
observed in the schizophrenia (33%; p=0.0098) and bipolar
groups (46%; p=0.003) compared to the control group (Figure 1).
Similarly, mean BDNF mRNA levels were significantly reduced
in schizophrenia group (34%; p=0.0027) and bipolar group
(40%; p=0.003) as compared to the control group (Figure 2). To
study the relationship between Spry2 and BDNF, Pearson’s
correlation was performed in schizophrenia group, bipolar group
and control group (Table 3). Significant high correlation between
Spry2 and BDNF mRNA expression levels was found in
schizophrenia group (p=0.01), bipolar group (p=0.02) and
control group (p=0.016).
Table 1. Correlations between BDNF or sprouty2 mRNA levels and confounding variables
Variable Control Schizophrenia Bipolar disorder
BDNF Sprouty2 BDNF Sprouty2 BDNF Sprouty2
r
a p
b rp rp rp rp rp
Age 20.085 0.587 20.100 0.236 0.244 0.188 0.088 0.608 20.022 0.899 20.166 0.481
PMI 20.012 0.482 20.075 0.673 0.185 0.287 0.017 0.922 0.234 0.206 20.277 0.132
Brain Ph 0.097 0.584 0.057 0.747 0.182 0.296 0.159 0.359 20.183 0.325 0.127 0.494
Brain weight 0.082 0.645 0.019 0.916 0.289 0.092 0.069 0.694 0.335 0.065 0.169 0.362
Refrigeration interval 20.127 0.431 20.153 0.488 0.099 0.365 0.086 0.528 20.121 0.263 0.083 0.611
Gender 20.077 0.512 0.081 0.711 0.022 0.878 20.033 0.854 0.070 0.692 20.118 0.527
Hemisphere 0.028 0.765 20.095 0.634 20.123 0.332 0.077 0.718 0.199 0.261 20.184 0.447
Smoking at the time of death 20.145 0.521 20.293 0.186 20.207 0.279 20.230 0.229 0.151 0.491 20.035 0.870
Age of onset 0.367 0.060 20.165 0.344 0.074 0.691 0.021 0.909
Duration of illness 20.243 0.160 0.332 0.051 20.299 0.102 20.031 0.099
Lifetime alcohol use 0.111 0.532 20.106 0.550 20.109 0.534 0.023 0.896 0.265 0.126 0.093 0.622
Lifetime substance use 0.067 0.707 0.163 0.358 20.096 0.600 20.067 0.709 0.199 0.282 0.163 0.381
aCorrelation value
bsignificance, p value from ANOVA
Pearson’s product moment correlation shown for age, PMI, brain pH, brain weight and refrigeration interval.
Kendall’s rank correlation tau shown for gender, hemisphere, smoking status, age of onset, duration of illness, lifetime alcohol use and lifetime substance abuse.
doi:10.1371/journal.pone.0001784.t001
Sprouty2 in Schizophrenia
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expression in rat frontal cortex
In order to test the potential effect of antipsychotic medication,
we evaluated mRNA as well as protein levels of BDNF and Spry2
in the frontal cortex of rats treated with haloperidol and
olanzapine. Haloperidol treated rats showed significant reduction
in mRNA (p=0.03) as well as protein (p=0.019) levels of BDNF,
where as olanzapine treated rats showed significant increase in
mRNA (p=0.023) as well as protein (p=0.045) levels of BDNF as
compared to vehicle-treated rats (Figure 3). Interestingly, signif-
icant increase in Spry2 mRNA (p=0.027) and protein (p=0.02)
expression was found in the frontal cortex of haloperidol-treated
rats whereas olanzapine-treated rats showed significant decrease in
Spry2 mRNA (p=0.018) and protein (p=0.041) expression as
compared to vehicle-treated rats.
Discussion
The present study for the first time shows that the expression of
Spry2, a key regulator of growth factor signaling, is altered in
schizophrenia and bipolar disorder compared with normal
controls. The key findings from the present study are: First, gene
expression of Spry2 and BDNF, a known inducer of Spry2, are
down-regulated in the DLPFC of schizophrenia and bipolar
subjects. Second, a significant positive correlation was observed
between Spry2 and BDNF in schizophrenia, bipolar and normal
subjects. Third, antipsychotic drug treatments showed differential
effects on mRNA as well as protein levels of Spry2 and BDNF in
rat frontal cortex.
The present study was conducted using the RNA samples from
DLPFC area of schizophrenia, bipolar and normal subjects.
Evidence from neuropsychological, neuroimaging, histopatholog-
ical, and neurochemical studies implicate the role of DLPFC in the
pathophysiology of schizophrenia [27]. In addition, a number of
studies have used the same set of samples obtained from Stanley
Array Collection to examine various pathological markers in
schizophrenia and bipolar disorder [28-30]. Though there are a
number of potential variables (age, PMI, brain pH, history of
substance abuse, cause of death, alcohol use, or smoking), which
can affect the quality of RNA as well as the gene expression status,
the results from the present study did not show any significant
correlation between BDNF or Spry2 mRNA levels and these
confounding variables.
Spry2 is the prototypical member of a new family of RTK-
signaling modulators, Sprouty proteins. The data from the present
study suggest that Spry2 gene expression is significantly decreased
in patients with either schizophrenia or bipolar disorder. It has
been previously reported that BDNF stimulates Spry2 expression
in neurons, and CREB and Sp1 are the two transcription factors
that regulate Spry2 promoter activity in response to BDNF [26].
To determine whether BDNF is involved in the mechanism that
contributed to decreased Spry2 expression in schizophrenia and
bipolar subjects, the present study examined the correlation
between the mRNA expression levels of Spry2 and BDNF. The
changes in Spry2 mRNA expression were significantly correlated
with BDNF mRNA expression in schizophrenia, bipolar and
normal subjects suggesting the importance of BDNF in the
regulation of Spry2 expression. However, further studies are
needed to establish whether reduced expression of BDNF is
sufficient to produce the altered expression of Spry2 in the DLPFC
of subjects with schizophrenia or bipolar disorder since other
growth factors, such EGF and FGF are also known to regulate
Spry2 expression, at least in in vitro conditions [31–33], and the
transcription factors CREB and Sp1 are involved in other growth
factor signaling pathways [34–35].
The data from antipsychotic-treated rats showed significant
effect of haloperidol and olanzapine on Spry2 mRNA and protein
levels in frontal cortex. The decrease in Spry2 expression after
haloperidol treatment might be due to the adverse side effects of
haloperidol after long-term treatment. It has been shown
previously that neurotoxic stresses lead to reduction of Spry2
expression in mature neurons and the reduced Spry2 protein levels
were significantly restored by BDNF treatment [26]. Long-term
haloperidol-treatment has been shown to increase neurotoxicity
markers, including pro-apoptotic proteins [36–37], and decrease
Table 2. Effect of antipsychotic treatment on BDNF and sprouty2 mRNA expression
Variable Group BDNF Sprouty2
Correlation p value Correlation p value
Antipsychotic use at the time of death
a Bipolar 20.176 0.457 20.261 0.265
Lifetime antipsychotic exposure
b Bipolar 20.178 0.346 20.246 0.189
Lifetime antipsychotic exposure
b Schizophrenia 20.202 0.244 20.255 0.139
aKendall’s rank correlation.
bSpearman’s correlation.
Lifetime antipsychotic dose in fluphenazine milligram equivalents.
p values are from ANOVA.
doi:10.1371/journal.pone.0001784.t002
Figure 1. Normalized Sprouty2 mRNA expression in schizo-
phrenia, bipolar and control subjects. Values are expressed as
mean6SEM. The number of individuals per sample is indicated within
each bar. Sprouty2 expression is significantly low in schizophrenia and
bipolar subjects as compared to control subjects. Level of significance
as compared to control subjects is shown above each bar.
doi:10.1371/journal.pone.0001784.g001
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compounds which can up-regulate BDNF signaling pathway have
been shown to prevent haloperidol treatment-induced neuronal
apoptosis [37]. Spry2 protein levels were decreased in rat frontal
cortex after olanzapine treatment with a parallel increase in BDNF
protein levels. Since Spry2 is a known inhibitory molecule of cell
proliferation and survival [24–25], data on decreased Spry2
expression after olanzapine treatment is in agreement with the
earlier reports that olanzapine treatment increases cell proliferation
in rat frontal cortex [38–39]. Again, as in haloperidol-treated rats,
the olanzapine-treated rats also showed an inverse relationship
between BDNF and Spry2 expression. It is important to note that
Spry2 expression can be induced upon growth factors such as EGF,
FGF and BDNF [26,31–33], whereas its expression can be
downregulated by TGF-b1 [40]. Therefore, the changes observed
in Spry2 expression would be the net effect of multiple growth factor
signaling pathways. Interestingly, rodent studies have indicated that
the beneficial effects of antipsychotic drugs are mediated through
growth factor signaling pathways [22–23]. This implies that the
changes in Spry2 expression with antipsychotic-treatment may
involve additionalmechanismsotherthanBDNFsignaling pathway.
The Spry2 gene regulates RTK signaling of many molecules
such as EGF, EGF, VEGF and BDNF. These growth factors as
well as neurotrophins play important roles in neuronal develop-
ment and plasticity. Spry2 is of particular interest as a downstream
target gene as well as a regulator for BDNF signaling. BDNF plays
an important role in regulating dopaminergic, glutamatergic, and
other neuronal signaling pathways, alterations of which are
observed in schizophrenia [41–42]. Moreover, postmortem studies
using brain samples from different cohorts showed changes in BDNF expression as well as the expression of its receptor, TrkB, in
different brain areas of subjects with schizophrenia [10–15]. There
are a number of other RTK-binding molecules in addition to
BDNF, which are implicated in schizophrenia. For example,
neuregulin 1 (NRG1) is a potential susceptibility gene for
schizophrenia [43], and alterations in NRG1-ErbB signaling
occur in the prefrontal cortex of schizophrenic patients [44–45].
NRG1-ErbB signaling regulates oligodendrocyte development and
myelination [44,46] and abnormalities in oligodendroglia and
myelin are reported in schizophrenia [47]. In addition, the role of
EGF has been investigated recently in the pathophysiology of
schizophrenia. Although one study reported abnormal expression
of EGF and its receptor in the forebrain and serum of subjects with
schizophrenia [48], another study could not find any significant
Table 3. Correlation between BDNF and sprouty2 mRNA
levels
Group Correlation
a p value
Control 0.407 0.016
Schizophrenia 0.414 0.010
Bipolar 0.400 0.020
aPearson’s correlation.
doi:10.1371/journal.pone.0001784.t003
Figure 2. Normalized BDNF mRNA expression in schizophrenia,
bipolar and control subjects. Values are expressed as mean6SEM.
The number of individuals per sample is indicated within each bar.
BDNF expression is significantly low in schizophrenia and bipolar
subjects as compared to control subjects. Level of significance as
compared to control subjects is shown above each bar.
doi:10.1371/journal.pone.0001784.g002
Figure 3. BDNF and Sprouty2 expression in the frontal cortex
of rats treated with haloperidol or olanzapine. Adult rats were
treated with haloperidol (2 mg/kg) or olanzapine (10 mg/kg) through
drinking water for 45 days, and (A) protein and (B) mRNA levels of BDNF
and Sprouty2 in frontal cortex were estimated after the treatment.
BDNF protein levels were measured by ELISA and Sprouty2 proteins
levels were estimated by Western blot analysis. mRNA levels of both
BDNF and Sprouty2 were estimated by qRT-PCR analysis. Open bars
represent haloperidol-treated rats whereas filled bars represent
olanzapine-treated rats. Values are expressed as fold change relative
to vehicle-treated rats. *p,0.05, n=10–12 per group.
doi:10.1371/journal.pone.0001784.g003
Sprouty2 in Schizophrenia
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compared to controls indicating the possibility that EGF may
serve as a state marker, i.e., as an index of symptom-linked deficits
[49]. A recent study showed that knockdown of endogenous
Disrupted-in-schizophrenia 1 (DISC1), a putative susceptibility
gene for psychoses such as schizophrenia and bipolar disorder, by
small interfering RNA in cortical neurons suppressed phosphor-
ylation of ERK, but the exact mechanisms remain unknown [50].
These studies indicate the possible involvement of Spry2 in the
function of many genes currently implicated in schizophrenia.
Growth factors function through RTKs and activate Ras-ERK
MAPK signaling to regulate numerous cellular events [51]. ERK
pathway has been implicated in regulation of neuronal function,
cell survival and in learning and memory [52]. Spry2 specifically
inhibits Ras-ERK MAPK signaling, leaving other MAPK and
PI3K pathways unaffected [31,53]. Spry2 exerts differential effects
on RTK-mediated signaling pathways at the level of Ras or Raf,
depending upon the cell type and growth factor [24–25,28]. Spry2
inhibits FGF-induced ERK activation by interfering with FRS2/
Shp2/Grb2 interactions [54], whereas it activates EGF-mediated
ERK activation by preventing c-Cbl-mediated ubiquitination and
endocytosis of activated EGFR [55]. Furthermore, a recent study
showed that the reduced level of Spry2 induced by TGF-b1i s
associated with inhibition of ERK activation in response to EGF
stimulation [40]. The available literature on ERK signaling in
postmortem brain samples from schizophrenia indicate a signif-
icant increase in ERK2 protein as well as mRNA levels in
cerebellum samples from schizophrenia subjects [56]. But,
accumulating evidence from rodent studies indicate differential
effects of antipsychotic drugs on ERK signaling in brain [57–59].
Therefore, additional studies are needed to correlate Spry2
expression and ERK signaling in schizophrenia, which will help
to identify the downstream signaling pathways regulated by Spry2
in schizophrenia.
Taken together, our data from postmortem as well as animal
studies indicate that the altered expression of Spry2 may be
secondary to antipsychotic treatment rather than to factors that
are significant in the disease process of either schizophrenia and/
or bipolar disorder. The lack of correlation between the expression
of Spry2 and antipsychotic medication at the time of death suggest
that additional studies using more number of subjects with/
without antipsychotic medication would be of great interest.
Further exploration of Spry2-related signal transduction pathways
will be helpful to design novel treatment strategies for schizophre-
nia and bipolar disorder.
Materials and Methods
Human Postmortem Samples
RNA samples from postmortem brain specimens, Brodmann’s
area 46 (in the DLPFC), from 35 individuals with schizophrenia,
31 individuals with bipolar disorder, and 34 psychiatrically normal
controls were obtained from the Stanley Array Collection of the
Stanley Brain Collection. A description of the Stanley Brain
Collection and more detailed demographics and samples’ quality
were previously reported [60]. RNA expression analysis was
conducted with the samples coded to keep investigators blind to
diagnostic status. At the time of sample decoding, diagnostic status
and a range of clinical variables were provided for analysis (see
Table 4).
RNA quantification
qRT-PCR was performed on a SmartCycler (Cepheid,
Sunnyvale, CA) using a SuperScript III Platinum SYBR Green
One-Step qRT-PCR kit (Invitrogen, Carlsbad, CA). Master mixes
were prepared and used in the PCR amplifications. A typical
reaction of a total volume of 25 ml consisted of 0.5 ml Superscript
III RT/Platinum Taq mix, 12.5 ml 2X SYBR Green Reaction
Mix (includes 0.4 mM of each dNTP and 6 mM MgSO4), 12.5
pMol of each of forward or reverse primers and 5 ml DEPC-
treated water. Approximately 0.5–1.0 mg RNA was used as
template. PCR amplification was done with an initial incubation
at 55uC for 120 sec, then at 95uC for 120 sec followed by 35 cycles
of 95uC for 15 sec, 50uC for 30 sec, 72uC for 30 sec and final
melting curve from 55uCt o9 5 uC with 0.2C/sec. The standard
curve used for determining the relative quantity in each sample
was constructed by the amplification of serial dilutions of cDNA.
Primer specificity was confirmed by melting curve analysis and
electrophoresis of PCR products on a 2% agarose gel to confirm
the presence of a single band of the predicted size. All
measurements were performed in triplicates. The data were
normalized to three control genes (glyceraldehyde 3-phosphate
dehydrogenase (GAPDH), ß-2-microglobulin (b2-MG) and ß-
actin) and a geometric mean of these genes. Primers utilized are
listed in Table 5.
Animal experiments
Animals. Adult male albino rats (weighing 225–250 g;
Harlan Sprague–Dawley, Inc., Indianapolis, IN, USA) were
housed singly under a 12-h light/12-h dark cycle and at a
constant temperature (25 ˚C) and humidity, and allowed free access
to food and water. Animal use procedures were performed after
being reviewed and approved by Medical College of Georgia
Committee on Animal Use for Research (CAURE) and Veterans
Affair Medical Center Subcommittee on Animal use. The
procedures were consistent with Association for Assessment and
Accreditation of Laboratory Animal Care (AAALAC) guidelines as
per Public Health Service Policy on Humane Care and Use of
Laboratory Animals.
Drug treatment. Haloperidol (Sigma Chemical Company,
St Louis, MO, USA) and olanzapine (A & A Pharmachem;
Toronto, ON, Canada) were dissolved in a 0.1-M acetic acid and
subsequently diluted (1:100) with tap water to administer the final
daily dose of drug. All drugs were prepared daily and administered
in solutions, which replaced drinking water. The amount of drug
intake was measured every day and adjustments were made
depending upon the fluid consumed and weight of the animals.
This method was preferred over multiple intramuscular injections
to maintain more constant drug levels and to reduce stress and
neuromuscular damage. Rats (n =10–12 per group) received
haloperidol (2 mg/kg/day) or olanzapine (10 mg/kg/day) for
45 days. The haloperidol dose was chosen based on previous
studies [23], in which it was found to result in plasma levels
comparable to therapeutic plasma levels in humans. This dose is
also comparable to the dose optimum for pharmacological effects
[61–63]. The choice of olanzapine, a representative atypical
antipsychotic, and its dose and duration of treatment was based on
their different pharmacological and clinical profiles, and
neurochemical effects reported in a large number of earlier
studies [23,64–66]. Tap water containing 0.1 M acetic acid was
used for the control group to assure that an unanticipated effect of
the vehicle was not present.
RNA quantification in rat frontal cortex samples
Frontal cortex samples from vehicle and antipsychotic-treated
rats were collected and RNA was extracted using a commercially
available kit (SV RNA Isolation, Promega, Madison, WI),
according to manufacturer’s instructions. mRNA was measured
Sprouty2 in Schizophrenia
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PCR kit as described earlier for human tissue with the following
primers: Sprouty2: (629–811 base pairs, Gen Bank accession No:
NM_011897, forward primer 59-GGGTCTCGGAGCAGTA-
CAAGG-39; reverse primer 59-GTAGGCATGCAGACC-
CAAAT-39), BDNF (1115-1363 base pairs, Gen Bank accession
No: NM_007540, forward primer 59-GCGGCAGATAAAAA-
GACTGC-39; reverse primer 59- CTTATGAATCGCCAGC-
CAAT -39) and housekeeping gene, ribosomal protein S3 (RPS3)
(284-466 base pairs, Gen Bank accession No: NM_012052,
forward primer 59-AATGAACCGAAGCACACCATA-39; re-
verse primer 59-ATCAGAGAGTTGACCGCAGTT-39).
Protein quantification in rat frontal cortex samples
Frontal cortex samples were collected and homogenized in ice-
cold buffer (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% SDS,
1% Nonidet P-40, 1% sodium deoxycholate) supplemented with
protease inhibitor cocktail (Sigma) containing 104 mM AEBSF,
0.08 mM aprotinin, 2 mM leupeptin, 4 mM bestatin, 1.5 mM
pepstatin A, and 1.4 mM E-64. After 15-min incubation on ice,
the extracts were clarified by centrifugation at 14,000 rpm for
15 min at 4uC and stored at –70uC. Protein concentrations were
determined by the bicinchoninic acid method (BCA Protein Assay
Kit, Sigma). Equal amounts of protein were resolved in SDS-
polyacrylamide gels and transferred electrophoretically onto a
nitrocellulose membrane (Bio-Rad, Hercules, California, United
States). Membranes were blocked for 1 h in TBST (10mM Tris-
HCl, pH 8.0, 138 mM NaCl, 2.7 mM KCl, and 0.05% Tween-
20) and 5% non-fat milk and incubated overnight with a rabbit
antibody to sprouty2 (Santa Cruz Biotechnology, Santa Cruz,
California, United States) and visualized using ECL (Pierce,
Rockford, Illinois, United States) with a secondary antibody
coupled to horseradish peroxidase. For actin normalization, blots
were incubated in strip buffer (62.5 mM Tris-HCl [pH 7.4], 2%
SDS, and 90 mM b-mercaptoethanol) at 65uC for 20 min with
agitation, followed by probing with a rabbit antibody to b-actin
(the antigen corresponds to amino acids 20–33, conserved in all
actin isoforms) as described above. To ensure that quantification
used an exposure that was within the linear range of the film used
to image the blot, a series of images with increasing exposure time
to the blot were developed. The intensity of the bands on each
image was quantified using Quantity one software (Bio-Rad) after
normalizing to the expression of b-actin.
Brain-derived Neurotrophic Factor (BDNF) Immunoassay
BDNF protein was measured with a conventional sandwich
ELISA using the BDNF Emax immunoassay system (Promega,
Madison, WI, USA) according to the protocol of the manufacturer.
Statistical analysis
The mean quantity value for Spry2 or BDNF mRNA for each
individual was normalized to the geometric mean of the three
housekeeping genes to obtain the relative amount of each
transcript in each individual. Continuous variables (age at death,
postmortem interval, brain pH, brain weight and refrigeration
interval) were tested by regression; dichotomous variables (gender,
brain hemisphere analyzed, smoking status at time of death, age of
onset, duration of illness, and history of exposure to antipsychotic
Table 4. Demographic data for post mortem brain samples.
Variable Control (N=34) Schizophrenia (N=35) Bipolar (N=31)
Age (years, mean6SD) 48.8267.57 42.5768.46 44.93610.99
Gender (male/female) 25/9 26/9 15/16
PMI (h, mean6SD) 29.47613.04 31.4615.54 36.61618.11
Refrigeration interval (h, mean6SD) 3.7162.60 5.9764.22 8.7467.22
Brain pH (mean6SD) 6.6160.27 6.4760.24 6.4660.28
Brain weight (g, mean6SD) 1443.216150.54 1442.116107.49 1410.646135.36
Age of onset (years, mean6SD) 0 21.2866.07 24.7768.95
Duration of illness (years, mean6SD) 0 21.28610.14 20.1669.88
Hemisphere (left/right) 16/18 17/18 18/13
Lifetime alcohol use 16 25 27
Lifetime drug abuse 5 21 22
History of psychosis 0 35 18
doi:10.1371/journal.pone.0001784.t004
Table 5. List of primer sequences used for postmortem studies.
Gen Bank
accession No Forward Reverse Base pairs
BDNF NM_170735 59-AAACATCCGAGGACAAGGTG-39 59-AGAAGAGGAGGCTCCAAAGG-3 634-883
Sprouty2 NM_005842 59-CCCCTCTGTCCAGATCCATA-39 59- CCCAAATCTTCCTTG CTCAG-39 695-896
GAPDH NM_002046 59-GAGTCAACGGATTTGGTCGT-39 59-TTGATTTTGGAGGGATCTCG-39 122-359
b2-MG NM_004048 59-CCAGCGTACTCCAAAGATTCA-39 59-TGCTCCACTTTTTCAATTCTCTC-39 123-201
b-actin NM_001101 59-GGACTTCGAGCAAGAGATGG–39 59-AGCACTGTGTTGGCGTACAG-39 736-969
doi:10.1371/journal.pone.0001784.t005
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PLoS ONE | www.plosone.org 6 March 2008 | Volume 3 | Issue 3 | e1784medication) and ordinal variables (lifetime alcohol use and lifetime
substance abuse) were tested by ANOVA. The strength of the
association with Spry2 or BDNF expression was measured with
Pearson’s product moment correlation for continuous variables
and Kendall’s rank correlation for binary and ordinal variables.
Effect of exposure to antipsychotics on Spry2 and BDNF mRNA
as well as protein levels in rats were analyzed by one-way ANOVA
followed by post-hoc Dunnett test with comparison to the vehicle-
treatment group. Differences in means between groups were
considered significant if p,0.05. SPSS version 14.0 software was
used for statistical analyses.
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